BRVE · Braveheart Bio
AI read · Good for BRVE
The AI's read
The findings give BHB-1893 a promising sign in people with obstructive HCM. The study was open-label, so the results need more testing. A Phase 2b study is planned, not completed.
Braveheart Bio shared new results from a year-long study of BHB-1893 for heart disease at a major conference.
Good for BRVE
Braveheart Bio reported that 79% of patients met a heart-flow measure after 52 weeks. The open-label study and planned next test limit how much this result proves, but the findings are encouraging.
Get alerts for BRVE
Follow Braveheart Bio (BRVE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BRVEFree on the App Store and Google Play, or on the web.